Epidemiology and risk factors for infections in myelodysplastic syndromes

被引:26
|
作者
Sullivan, L. R. [1 ]
Sekeres, M. A. [2 ]
Shrestha, N. K. [1 ]
Maciejewski, J. P. [2 ]
Tiu, R. V. [2 ]
Butler, R. [3 ]
Mossad, S. B. [1 ]
机构
[1] Cleveland Clin, Dept Infect Dis, Inst Med, Cleveland, OH 44195 USA
[2] Cleveland Clin, Leukemia Program, Dept Hematol Oncol & Blood Disorders, Taussig Canc Inst, Cleveland, OH 44195 USA
[3] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA
关键词
myelodysplastic syndrome; infection; risk factors; WORLD-HEALTH-ORGANIZATION; EUROPEAN ORGANIZATION; NEUTROPENIC PATIENTS; MYELOID NEOPLASMS; DISEASES-SOCIETY; SUPPORTIVE CARE; SCORING SYSTEM; ACUTE-LEUKEMIA; CLASSIFICATION; COMPLICATIONS;
D O I
10.1111/tid.12130
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We conducted a case-control study to describe the epidemiology and risk factors for infections requiring hospitalization in patients with myelodysplastic syndromes (MDS). Of 497 patients identified, 103 patients developed 201 episodes of infection. The probability of acquiring an infection 1year from date of MDS diagnosis was 15% (95% confidence interval [CI] 12-18%). Patients developing infections had decreased survival compared to those who did not (P=0.007). Significant risk factors for infection were higher risk MDS (hazard ratio [HR]=2.7, 95% CI=1.7-4.1, P<0.0001), nadir absolute neutrophil count <500/mL (HR=1.8, 95% CI=1.2-2.7, P<0.007), chronic obstructive pulmonary disease (HR=2.6, 95% CI=1.4-4.9, P<0.003), history of other malignancy (HR 2.0, 95% CI=1.3-3.1, P<0.003), and autoimmune disease (HR 2.9, 95% CI=1.4-6.0, P<0.005). Age, nadir platelet count <20,000/mL, diabetes mellitus, and MDS treatment were not significant risk factors. Pneumonia was the most common infection, and bacteria the predominant pathogens.
引用
收藏
页码:652 / 657
页数:6
相关论文
共 50 条
  • [21] Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS)
    Yarosh, Rina
    Roesler, Michelle A.
    Murray, Thomas
    Cioc, Adina
    Hirsch, Betsy
    Nguyen, Phuong
    Warlick, Erica
    Poynter, Jenny N.
    CANCER CAUSES & CONTROL, 2021, 32 (03) : 241 - 250
  • [22] Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France
    Nisse, C
    Haguenoer, JM
    Grandbastien, B
    Preudhomme, C
    Fontaine, B
    Brillet, JM
    Lejeune, R
    Fenaux, P
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (04) : 927 - 935
  • [23] Risk factors of myelodysplastic syndromes: a case-control study
    Strom, SS
    Gu, Y
    Gruschkus, SK
    Pierce, SA
    Estey, EH
    LEUKEMIA, 2005, 19 (11) : 1912 - 1918
  • [24] Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it
    Zeidan, Amer M.
    Shallis, Rory M.
    Wang, Rong
    Davidoff, Amy
    Ma, Xiaomei
    BLOOD REVIEWS, 2019, 34 : 1 - 15
  • [25] An update on treatment of higher risk myelodysplastic syndromes
    Rahme, Ramy
    Ades, Lionel
    EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (01) : 61 - 70
  • [26] Azacitidine for the Treatment of Lower Risk Myelodysplastic Syndromes
    Musto, Pellegrino
    Maurillo, Luca
    Spagnoli, Alessandra
    Gozzini, Antonella
    Rivellini, Flavia
    Lunghi, Monia
    Villani, Oreste
    Aloe-Spiriti, Maria Antonietta
    Venditti, Adriano
    Santini, Valeria
    CANCER, 2010, 116 (06) : 1485 - 1494
  • [27] The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome
    Cordoba, I.
    Gonzalez-Porras, J. R.
    Such, E.
    Nomdedeu, B.
    Luno, E.
    de Paz, R.
    Carbonell, F.
    Vallespi, T.
    Ardanaz, M.
    Ramos, F.
    Marco, V.
    Bonanad, S.
    Sanchez-Barba, M.
    Costa, D.
    Bernal, T.
    Sanz, G. F.
    Canizo, M. C.
    LEUKEMIA RESEARCH, 2012, 36 (03) : 287 - 292
  • [28] Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes
    Melody, Megan
    Al Ali, Najla
    Zhang, Ling
    Ramadan, Hanadi
    Padron, Eric
    Sallman, David
    Sweet, Kendra
    Lancet, Jeffrey
    List, Alan
    Bennett, John M.
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (05): : 324 - 328
  • [29] Mannuronic Acid in Low-Risk and Intermediate-1-Risk Myelodysplastic Syndromes
    Ghaderi, Afshin
    Nodehi, Sayyed Reza Safaee
    Bakhtiari, Tahereh
    Aslani, Mona
    Aghazadeh, Zahra
    Matsuo, Hidenori
    Rehm, Bernd H. A.
    Cuzzocrea, Salvatore
    Mirshafiey, Abbas
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (07): : 879 - 888
  • [30] Epidemiology, risk factors, and impact of bacterial infections on outcomes for pancreatic grafts
    Bodro, Marta
    Ferrer, Joana
    Jose Ricart, Maria
    Sanclemente, Gemma
    Linares, Laura
    Cervera, Carlos
    Cofan, Frederic
    Ventura-Aguiar, Pedro
    Angel Lopez-Boado, Miguel
    Marco, Francesc
    Fuster, Josep
    Carlos Garcia-Valdecasas, Juan
    Moreno, Asuncion
    CLINICAL TRANSPLANTATION, 2018, 32 (08)